Terns Pharmaceuticals Inc banner

Terns Pharmaceuticals Inc
NASDAQ:TERN

Watchlist Manager
Terns Pharmaceuticals Inc Logo
Terns Pharmaceuticals Inc
NASDAQ:TERN
Watchlist
Price: 52.61 USD -0.04% Market Closed
Market Cap: $5.6B

During the last 3 months Terns Pharmaceuticals Inc insiders have not bought any shares, and sold 3m USD worth of shares. The stock price has increased by 42% over this period (open performance analysis).

The last transaction was made on Apr 1, 2026 by Kuriakose Emil , who sold 49.7k USD worth of TERN shares.

Last Transactions:
Kuriakose Emil
$-49.7k
Burroughs Amy L.
$-550.1k
Burroughs Amy L.
$-89.1k
Burroughs Amy L.
$-2.3m
Burroughs Amy L.
$-2.7m
Kuriakose Emil
Chief Financial Officer
$-7.9k
Quigley Jill M.
$-441.4k
Kuriakose Emil
$-7.4k
Kuriakose Emil
$-3.6k
Gengos Andrew
$+19.6k
Burroughs Amy L.
$+90.2k
Gengos Andrew
$+19.7k
Gengos Andrew
$+18.8k
Kuriakose Emil
$-2.4k
Quigley Jill M.
$-50.8k
Vignola Mark J.
$-52.5k
Vignola Mark J.
$-46.5k
Kuriakose Emil
$-25.6k
Quigley Jill M.
$-35.7k
Burroughs Amy L.
$+110.5k
Jung Melita Sun
$+11.5k
Burroughs Amy L.
$+2.6k
Lu Hongbo
$+2m
Vignola Mark J.
$-110k
Quigley Jill M.
$-172.4k
Quigley Jill M.
$-66.4k
Quigley Jill M.
$-47.1k
Quigley Jill M.
$-4k
Gordon Carl L
$-40.1k
Orbimed Advisors Llc
$-40.1k
Orbimed Advisors Llc
$-394.3k
Gordon Carl L
$-394.3k
View All Transactions

During the last 3 months Terns Pharmaceuticals Inc insiders have not bought any shares, and sold 3m USD worth of shares. The stock price has increased by 42% over this period (open performance analysis).

The last transaction was made on Apr 1, 2026 by Kuriakose Emil , who sold 49.7k USD worth of TERN shares.

Sold
0-3
months
3m USD
2
3-6
months
3.2m USD
3
6-9
months
7.4k USD
1
9-12
months
3.6k USD
1
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
2
148.3k USD

Terns Pharmaceuticals Inc
Insider Trading Chart

Terns Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Terns Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Terns Pharmaceuticals Inc
Glance View

Market Cap
5.6B USD
Industry
Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.

TERN Intrinsic Value
LOCKED
Unlock

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett